跳至主要内容
临床试验/NCT01719263
NCT01719263已完成不适用

Sequential Segmental Treatment of Emphysema With Upper Lobe Predominance (STEP-UP) Study

Uptake Medical Corp31 个研究点 分布在 6 个国家目标入组 69 人开始时间: 2013年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
69
试验地点
31
主要终点
Forced expiratory volume in 1-second (FEV1) compared to active comparator

研究概览

简要总结

This study is designed to demonstrate safety and efficacy in patients with severe upper lobe predominant emphysema. For validity of the study, the results will be compared to patients that receive optimal medical therapy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Heterogeneous emphysema with upper lobe predominance in both lungs
  • FEV1 between 20% and 45% predicted
  • Residual volume (RV) > 150% predicted
  • Post-rehabilitation 6-minute walk test > 140 meters

排除标准

  • More than 3 COPD related hospitalizations requiring antibiotics in past 12 months
  • FEV1 < 20% predicted
  • DLCO < 20% predicted or immeasurable DLCO
  • Body mass index (BMI) < 18kg/m2 or > 32 kg/m2
  • History of any of the following:
  • Left ventricular ejection fraction (EF) ≤ 40%
  • Myocardial infarction or acute coronary syndrome in previous year
  • Hospitalization due to left ventricular failure in previous 3 years

结局指标

主要结局

Forced expiratory volume in 1-second (FEV1) compared to active comparator

时间窗: Year 1

Quality of Life (SGRQ)

时间窗: Year 1

次要结局

  • Responder rate for FEV1 % difference from baseline(Year 1)
  • Responder rate 6MWD meter difference from baseline(Year 1)
  • Responder rate SGRQ pts difference from baseline(Year 1)
  • Lobar Volume Reduction HRCT(Year 1)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (31)

Loading locations...

相似试验